FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2982888477> ?p ?o ?g. }

• W2982888477 endingPage "1420" @default.
• W2982888477 startingPage "1409" @default.
• W2982888477 abstract "Therapeutic success of targeted therapy with BRAF inhibitors (BRAFi) for melanoma is limited by resistance development. Observations from preclinical mouse models and recent insights into the immunological effects caused by BRAFi give promise for future development of combination therapy for human melanoma. In our study, we used the transplantable D4M melanoma mouse model with the BRAF V600E mutation and concomitant PTEN loss in order to characterize alterations in tumor‐infiltrating effector immune cells when tumors become resistant to BRAFi. We found that BRAFi‐sensitive tumors displayed a pronounced inflammatory milieu characterized by high levels of cytokines and chemokines accompanied by an infiltration of T and NK cells. The tumor‐infiltrating effector cells were activated and produced high levels of IFN‐γ, TNF‐α and granzyme B. When tumors became resistant and progressively grew, they reverted to a low immunogenic state similar to untreated tumors as reflected by low mRNA levels of proinflammatory cytokines and chemokines and fewer tumor‐infiltrating T and NK cells. Moreover, these T and NK cells were functionally impaired in comparison to their counterparts in BRAFi‐sensitive tumors. Their effector cell function could be restored by additional peritumoral treatment with the TLR7 agonist imiquimod, a clinically approved agent for nonmelanoma skin cancer. Indeed, resistance to BRAFi therapy was delayed and accompanied by high numbers of activated T and NK cells in tumors. Thus, combining BRAFi with an immune stimulating agent such as a TLR ligand could be a promising alternative approach for the treatment of melanoma." @default.
• W2982888477 created "2019-11-22" @default.
• W2982888477 creator A5018175236 @default.
• W2982888477 creator A5031193075 @default.
• W2982888477 creator A5031642802 @default.
• W2982888477 creator A5034752224 @default.
• W2982888477 creator A5044218981 @default.
• W2982888477 creator A5057106878 @default.
• W2982888477 creator A5071016708 @default.
• W2982888477 creator A5073889603 @default.
• W2982888477 creator A5078633219 @default.
• W2982888477 creator A5087654744 @default.
• W2982888477 date "2019-12-04" @default.
• W2982888477 modified "2023-10-10" @default.
• W2982888477 title "A TLR7 agonist strengthens T and NK cell function during BRAF‐targeted therapy in a preclinical melanoma model" @default.
• W2982888477 cites W1606003850 @default.
• W2982888477 cites W1834835434 @default.
• W2982888477 cites W1895814318 @default.
• W2982888477 cites W1964444828 @default.
• W2982888477 cites W1974056979 @default.
• W2982888477 cites W1991769418 @default.
• W2982888477 cites W1994993231 @default.
• W2982888477 cites W1996436013 @default.
• W2982888477 cites W2004314683 @default.
• W2982888477 cites W2017187984 @default.
• W2982888477 cites W2020543365 @default.
• W2982888477 cites W2020888257 @default.
• W2982888477 cites W2037723794 @default.
• W2982888477 cites W2042699075 @default.
• W2982888477 cites W2049267118 @default.
• W2982888477 cites W2061135112 @default.
• W2982888477 cites W2083903310 @default.
• W2982888477 cites W2087569038 @default.
• W2982888477 cites W2089738194 @default.
• W2982888477 cites W2102557111 @default.
• W2982888477 cites W2103675014 @default.
• W2982888477 cites W2107598346 @default.
• W2982888477 cites W2111651073 @default.
• W2982888477 cites W2114903025 @default.
• W2982888477 cites W2116376943 @default.
• W2982888477 cites W2124039716 @default.
• W2982888477 cites W2125395855 @default.
• W2982888477 cites W2126758513 @default.
• W2982888477 cites W2127437403 @default.
• W2982888477 cites W2128542677 @default.
• W2982888477 cites W2130650675 @default.
• W2982888477 cites W2131884978 @default.
• W2982888477 cites W2157385919 @default.
• W2982888477 cites W2163188200 @default.
• W2982888477 cites W2166262263 @default.
• W2982888477 cites W2169988783 @default.
• W2982888477 cites W2172076789 @default.
• W2982888477 cites W2320718432 @default.
• W2982888477 cites W2416097913 @default.
• W2982888477 cites W2531876842 @default.
• W2982888477 cites W2558219863 @default.
• W2982888477 cites W2588812529 @default.
• W2982888477 cites W2588948315 @default.
• W2982888477 cites W2605233023 @default.
• W2982888477 cites W2612431515 @default.
• W2982888477 cites W2617691667 @default.
• W2982888477 cites W2766735647 @default.
• W2982888477 cites W2781525129 @default.
• W2982888477 cites W2787835497 @default.
• W2982888477 cites W2791044761 @default.
• W2982888477 cites W2808909747 @default.
• W2982888477 cites W2939963348 @default.
• W2982888477 cites W2948716731 @default.
• W2982888477 cites W2948740360 @default.
• W2982888477 cites W2948884915 @default.
• W2982888477 doi "https://doi.org/10.1002/ijc.32777" @default.
• W2982888477 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7003881" @default.
• W2982888477 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31702822" @default.
• W2982888477 hasPublicationYear "2019" @default.
• W2982888477 type Work @default.
• W2982888477 sameAs 2982888477 @default.
• W2982888477 citedByCount "22" @default.
• W2982888477 countsByYear W29828884772020 @default.
• W2982888477 countsByYear W29828884772021 @default.
• W2982888477 countsByYear W29828884772022 @default.
• W2982888477 countsByYear W29828884772023 @default.
• W2982888477 crossrefType "journal-article" @default.
• W2982888477 hasAuthorship W2982888477A5018175236 @default.
• W2982888477 hasAuthorship W2982888477A5031193075 @default.
• W2982888477 hasAuthorship W2982888477A5031642802 @default.
• W2982888477 hasAuthorship W2982888477A5034752224 @default.
• W2982888477 hasAuthorship W2982888477A5044218981 @default.
• W2982888477 hasAuthorship W2982888477A5057106878 @default.
• W2982888477 hasAuthorship W2982888477A5071016708 @default.
• W2982888477 hasAuthorship W2982888477A5073889603 @default.
• W2982888477 hasAuthorship W2982888477A5078633219 @default.
• W2982888477 hasAuthorship W2982888477A5087654744 @default.
• W2982888477 hasBestOaLocation W29828884771 @default.
• W2982888477 hasConcept C13373296 @default.
• W2982888477 hasConcept C164027704 @default.
• W2982888477 hasConcept C167672396 @default.
• W2982888477 hasConcept C183193105 @default.
• W2982888477 hasConcept C203014093 @default.

• next